Singapore markets open in 3 hours 3 minutes

Straits Times Index
3,313.48
+8.49(+0.26%)
S&P 500
5,303.27
+6.17(+0.12%)
Dow
40,003.59
+134.19(+0.34%)
Nasdaq
16,685.97
-12.33(-0.07%)
Bitcoin USD
66,298.69
-597.55(-0.89%)
CMC Crypto 200
1,353.24
-20.60(-1.50%)

BPMC Jun 2024 75.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.7200

0.0000

(0.00%)

As of 03:25PM EDT. Market open.

Zacks
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
PR Newswire
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 6,400 shares of its common stock and an aggregate of 3,200 restricted stock units (RSUs) to two new employees under Blueprint Medicines' 2020 Inducement Plan.
Zacks
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.